Cat. No.: HY-17439

Salinomycin sodium salt

Name: Salinomycin sodium salt
Brand: MedChemExpress
SKU: HY-17439
Price: 60.00 USD
Availability: InStock
Rating: 5 (52 reviews)

(Synonyms: Salinomycin sodium; Sodium salinomycin)

52 Cited Publications

고객리뷰

Based on 52 publication(s) in Google Scholar

Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of Wnt/β-catenin signaling. Salinomycin sodium salt acts on the Wnt/Fzd/LRP complex, blocks Wnt-induced LRP6 phosphorylation, and causes degradation of the LRP6 protein. Salinomycin sodium salt shows selective activity against human cancer stem cells.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity : 99.81%
CAS No.: 55721-31-8
화학식: C₄₂H₆₉NaO₁₁
분자량:772.98

보관:

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Salinomycin sodium salt Chemical Structure

CAS No.: 55721-31-8

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (52)
용액&용해도
- In Vitro
- In Vivo
Protocol
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

Wnt/β-catenin^[1]

All Wnt Isoforms :

All Antibiotic Isoforms :

All Parasite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC₅₀	0.002 μM Compound: 92124650	HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells	[PMID: 22586124]
HepG2	IC₅₀	58 μM Compound: 92124650	HARVARD: Cytotoxicity in HepG2 cell line HARVARD: Cytotoxicity in HepG2 cell line	[PMID: 22586124]
MCF7	IC₅₀	0.59 μM Compound: 74	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 30684870]

In Vitro

Salinomycin (0.1-8 μM; 48 h) inhibits the growth of HUVECs in a dose-dependent manner, accounting for 32.1 and 59.2% inhibition at 4 and 8 μM, respectively. HUVECs exposed to 2, 4 and 8 μM of Salinomycin for 48 h show a dose-dependent reduction in cell number and a change in cell morphology. Salinomycin (4 μM) treatment effectively inhibits HUVEC migration and invasion, and significantly disrupt the capillary-like tube formation of HUVECs. Salinomycin significantly suppresses the expression levels of phosphorylated (p)-FAK in a time- and dose-dependent manner in HUVECs. Salinomycin inhibits HUVEC angiogenesis by disturbing the VEGF-VEGFR2-AKT signaling axis^[1].
Combination of RSVL and Salinomycin synergistically inhibits the proliferation of TNBC (MDA-MB-231) cells. RSVL and Salinomycin effectively reduce wound healing, colony and tumorosphere forming capability in TNBC cells. Synergistic combination of RSVL and Salinomycin induces apoptosis in both culture conditions by significant upregulation of Bax with decreased Bcl-2 expression as comparison to untreated and alone drug treatments^[2]. Salinomycin (0, 2, 4, 8 and 16 μM) significantly inhibits the proliferation of A2780 and SK-OV-3 cell lines in a dose- and time-dependent manner, (IC_{50 24h}: 13.8 μM, IC_{50 48h}: 6.888 μM and IC_{50 72h}: 4.382 μM for A2780 cell lines), (IC_{50 24h}: 12.7 μM, IC_{50 48h}: 9.869 μM and IC_{50 72h}: 5.022 μM for SK-OV-3 cell lines). Salinomycin blocks the Wnt/β-catenin pathway in EOC cells^[3]. Salinomycin (2 μM) reduces cancer cell proliferation, inhibits STAT3 phosphorylation and P38 and β-catenin expressions, and suppresses epithelial-mesenchymal transition in colorectal cancer cells. Salinomycin (1-5 μM) inhibits cancer cell proliferation and STAT3 signaling in colorectal cancer cells. Furthermore, Salinomycin activates Akt (Ser 473) and down-regulates Hsp27 (Ser 82) phosphorylation in HT-29 and SW480. Salinomycin down-regulates hTERT and reduces telomerase activity when combined with telomerase inhibitor^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Salinomycin (5 and 10 mg/kg) significantly supresses the average tumor volume and tumor weight. Salinomycin hinders the U251 human glioma cell growth in vivo via inhibition of angiogenesis with involvement of AKT and FAK dephosphorylation^[1]. Salinomycin (0.5 mg/kg b.wt.) enhances the mean survival time of the tumor bearing Swiss albino mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 55721-31-8
Appearance Solid
분자량 772.98
화학식 C₄₂H₆₉NaO₁₁
Color White to yellow
SMILES

[H][C@]1([C@](C)(CC2)O[C@]32[C@H](O)C=C[C@]4(O[C@]([H])([C@@H](CC)C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O[Na])=O)([H])CC[C@@H]5C)=O)[C@@H](C)C[C@H]4C)O3)CC[C@@](CC)(O)[C@H](C)O1
Synonyms

Salinomycin sodium; Sodium salinomycin
선적

Room temperature in continental US; may vary elsewhere.
보관

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Publications (52)

All WBOthers

Sort by:

Journal Impact Factor

Nat Commun

ATG8ylation-mediated tonoplast invagination mitigates vacuole damage. [Abstract]

2025 Jul 18;16(1):6621. PMID: 40681515

Salinomycin sodium salt purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]

Salinomycin sodium salt (20 μM). The formation of membrane-like structures of GFP-ATG8a in response to three ionophores.
Adv Sci (Weinh)

Targeting Fibrotic Scarring by Mechanoregulation of Il11ra1+/Itga11+ Fibroblast Patterning Promotes Axon Growth after Spinal Cord Injury. [Abstract]

2025 Sep 9:e13476. PMID: 40923460
Adv Sci (Weinh)

A Novel tRF, HCETSR, Derived From tRNA-Glu/TTC, Inhibits HCC Malignancy by Regulating the SPBTN1-catenin Complex Axis. [Abstract]

2025 Apr;12(13):e2415229. PMID: 39921434
J Control Release

Combined nanomedicines targeting colorectal cancer stem cells and cancer cells. [Abstract]

2020 Oct 10:326:387-395. PMID: 32702392
Cell Death Dis

PDIA4 confers resistance to ferroptosis via induction of ATF4/SLC7A11 in renal cell carcinoma. [Abstract]

2023 Mar 11;14(3):193. PMID: 36906674
Pharmacol Res

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]

2020 May:155:104751. PMID: 32151678
Biosens Bioelectron

Proximity labeling-assisted click conjugation for electrochemical analysis of specific subpopulations in circulating extracellular vesicles. [Abstract]

2024 Jul 1:255:116245. PMID: 38555770
Cell Commun Signal

M2 macrophages promote myofibroblast differentiation of LR-MSCs and are associated with pulmonary fibrogenesis. [Abstract]

2018 Nov 23;16(1):89. PMID: 30470231

Salinomycin sodium salt purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2018 Nov 23;16(1):89. [Abstract]

The expression of collagen I, α-smooth muscle actin (α-SMA), and Sca-1 in lung tissues is measured by western blotting in the treatment of Saline, Salinomycin, Bleomycin+Vehicle, and Bleomycin+ Salinomycin.
Acta Biomater

Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy. [Abstract]

2022 Oct 15:152:380-392. PMID: 36028199
Int J Nanomedicine

Salinomycin-Loaded Small-Molecule Nanoprodrugs Enhance Anticancer Activity in Hepatocellular Carcinoma. [Abstract]

2020 Sep 15:15:6839-6854. PMID: 32982236
Int J Mol Med

Simvastatin promotes endothelial dysfunction by activating the Wnt/β‑catenin pathway under oxidative stress. [Abstract]

2019 Oct;44(4):1289-1298. PMID: 31432100
Mol Med

The mechanism of enterogenous toxin methylmalonic acid aggravating calcium-phosphorus metabolic disorder in uremic rats by regulating the Wnt/β-catenin pathway. [Abstract]

2025 Jan 22;31(1):19. PMID: 39844078
EMBO Mol Med

A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. [Abstract]

2019 Oct;11(10):e9930. PMID: 31476112
Cell Rep

Controlling mitochondrial membrane architecture via MIC60 determines viral replication to promote anti-viral immunity. [Abstract]

2025 Jul 22;44(7):115922. PMID: 40628273
Anal Chem

Label-Free Isolation of Low-Adhesion Cells with Stem Properties for Cancer Stem Cell-Specific Drug Evaluation. [Abstract]

2023 Apr 11;95(14):6191. PMID: 36122350
Talanta

Fluorescence-activated cell sorting-based efficient screening of monensin monoclonal antibodies and applications in lateral flow immunoassay. [Abstract]

2025 Oct 1:293:128128. PMID: 40222095
Eur J Med Chem

A peptide-salinomycin conjugate with a bystander effect reduces the stemness characteristics of ovarian cancer cells and enhances drug sensitivity. [Abstract]

2024 Oct 5:276:116701. PMID: 39067438
Cell Biosci

Modaline sulfate promotes Oct4 expression and maintains self-renewal and pluripotency of stem cells through JAK/STAT3 and Wnt signaling pathways. [Abstract]

2021 Aug 4;11(1):156. PMID: 34348786

Salinomycin sodium salt purchased from MedChemExpress. Usage Cited in: Cell Biosci. 2021 Aug 4;11(1):156. [Abstract]

Salinomycin (0.0078125 μg/ml; for 24 h) reverses the MDLS-induced up-regulation of Oct4. The expression of Oct4 is determined using Western blot analysis.
Biomed J

Repurposing old drugs as antiviral agents for coronaviruses. [Abstract]

2020 Aug;43(4):368-374. PMID: 32563698
RSC Adv

BSA-MnO2-SAL multifunctional nanoparticle-mediated M1 macrophages polarization for glioblastoma therapy. [Abstract]

2021 Nov 2;11(56):35331-35341. PMID: 35493189
J Mol Cell Biol

The inwardly rectifying potassium channel KCNJ12 regulates the stemness of hepatocellular carcinoma cells through the Wnt/β-catenin pathway. [Abstract]

2025 Dec 2:mjaf048. PMID: 41328864
Hepatol Commun

Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening. [Abstract]

2025 May 16;9(6):e0706. PMID: 40377490
Int J Pharm

Polylactic Acid Based Biodegradable Hybrid Block Copolymeric Nanoparticle Mediated Co-delivery of Salinomycin and Doxorubicin for Cancer Therapy. [Abstract]

2023 Mar 25:635:122779. PMID: 36842520
Eur J Pharmacol

To explore the potential combined treatment strategy for colorectal cancer: Inhibition of cancer stem cells and enhancement of intestinal immune microenvironment. [Abstract]

2025 Jul 5:998:177533. PMID: 40120791
Cell Oncol (Dordr)

Inhibition of EREG/ErbB/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFβ and Hedgehog signal pathway. [Abstract]

2024 Dec;47(6):2201-2215. PMID: 39373858
Int J Mol Sci

The Effect of Cholesterol Efflux on Endothelial Dysfunction Caused by Oxidative Stress. [Abstract]

2023 Mar 21;24(6):5939. PMID: 36983012
Int J Mol Sci

Sphingomyelin Synthase 2 Promotes Endothelial Dysfunction by Inducing Endoplasmic Reticulum Stress. [Abstract]

2019 Jun 12;20(12):2861. PMID: 31212751
Nanoscale

Folic acid-targeted redox responsive polylactic acid-based nanoparticles co-delivering pirarubicin and salinomycin suppress breast cancer tumor growth in vivo. [Abstract]

2024 Nov 7;16(43):20131-20146. PMID: 39420738
AAPS PharmSciTech

Concomitant Delivery of Pirarubicin and Salinomycin Synergistically Enhanced the Efficacy of Cancer Therapy and Reduced the Risk of Cancer Relapse. [Abstract]

2024 Sep 7;25(7):211. PMID: 39242397
Sci Rep

PFDN2 stabilizes PYCR2 to activate Wnt/β-catenin signaling and promote colorectal cancer progression. [Abstract]

2026 Feb 9;16(1):7909. PMID: 41656306
Cancers (Basel)

Physical Cues in the Microenvironment Regulate Stemness-Dependent Homing of Breast Cancer Cells. [Abstract]

2020 Aug 5;12(8):2176. PMID: 32764400
Oncol Rep

Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells. [Abstract]

2018 Aug;40(2):877-886. PMID: 29989650

Salinomycin sodium salt purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Aug;40(2):877-886. [Abstract]

Salinomycin (SAL) has a pro-apoptotic effect on NB4 and HL-60 cells. The apoptosis-related protein levels of Bax and Bcl-2 are assessed by western blotting with the β-actin protein as an internal control.
ACS Infect Dis

Ex Vivo Phenotypic Screening of Two Small Repurposing Drug Collections Identifies Nifuratel as a Potential New Treatment against Visceral and Cutaneous Leishmaniasis. [Abstract]

2021 Aug 13;7(8):2390-2401. PMID: 34114790
Antiviral Res

Salinomycin inhibits orthopoxvirus infection in vitro and in vivo by blocking endosomal acidification. [Abstract]

2026 May:249:106403. PMID: 41941992
FASEB J

Stem Cells From the Apical Papilla Cultured in Spheroids Spontaneously Differentiate Into Odontoblasts via N-Cadherin Downregulation. [Abstract]

2025 Dec 31;39(24):e71350. PMID: 41399894
Biochim Biophys Acta Mol Cell Res

Salinomycin inhibits SREBP1 to sensitize ferroptosis and ameliorate sorafenib resistance in clear cell renal cell carcinoma. [Abstract]

2025 Aug;1872(6):119989. PMID: 40360020
Viruses

Ionophore Antibiotics Inhibit Type II Feline Coronavirus Proliferation In Vitro. [Abstract]

2022 Aug 6;14(8):1734. PMID: 36016355
J Bioenerg Biomembr

Pre-clinical evidence that salinomycin is active against retinoblastoma via inducing mitochondrial dysfunction, oxidative damage and AMPK activation. [Abstract]

2021 Oct;53(5):513-523. PMID: 34365583
Int J Hyperthermia

Eliminating cancer stem cells can inhibit progression of residual hepatocellular carcinoma after radiofrequency ablation. [Abstract]

2026 Dec;43(1):2643510. PMID: 41883111
Exp Ther Med

Synthesis of chemical tools to improve water solubility and promote the delivery of salinomycin to cancer cells. [Abstract]

2020 Mar;19(3):1835-1843. PMID: 32104239
Leuk Lymphoma

Salinomycin sodium exerts anti diffuse large B-cell lymphoma activity through inhibition of LRP6-mediated Wnt/β-catenin and mTORC1 signaling. [Abstract]

2023 Jun;64(6):1151-1160. PMID: 37092573
Res Sq

2026 Jan 9.
SSRN

2025 Dec 2.
SSRN

2024 Nov 12.
bioRxiv

2024 September 18.
bioRxiv

2024 September 07.
Chemosphere

PFDA promotes cancer metastasis through macrophage M2 polarization mediated by Wnt/β-catenin signaling. [Abstract]

2024 Aug:362:142758. PMID: 38969224
bioRxiv

2023 Jun 25.
bioRxiv

2023 Jan 17.
Research Square Print

2023 Jan 6th.
Norwegian University of Science and Technology

2021 Oct.
bioRxiv

2020 Jun.

용액&용해도

In Vitro:

DMSO : 100 mg/mL (129.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2937 mL

6.4685 mL

12.9369 mL

5 mM

0.2587 mL

1.2937 mL

2.5874 mL

10 mM

0.1294 mL

0.6468 mL

1.2937 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

The effect of Salinomycin on HUVEC growth is determined by MTT assay. Briefly, HUVECs (6,000 cells/well) are seeded in 96-well culture plates for 24 h and incubated with different concentrations of Salinomycin. In the preliminary experiments, Salinomycin treatment for 12, 24, 48 and 72 h shows time-dependent effects on cell growth inhibition. However, treatment for 48 h is the optimal time and is selected for further mechanism evaluation. After Salinomycin treatment for 48 h, 20 µL/well of MTT solution (5 mg/mL) is added and incubated for 5 h. The medium is aspirated and replaced with 200 µL/well of DMSO to dissolve the formazan Salinomycint formed. The color intensity of the formazan solution is measured at 570 nm by a microplate spectrophotometer. The cell viability is expressed as % of the control (as 100%).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Human glioma U251 cells (1×10⁷) suspended in 100 µL PBS are injected into the right lower hind flank of each 6-week-old male nude mouse. The mice are then randomly assigned into three groups of 10 mice in each group. After one week, Salinomycin (5 and 10 mg/kg) is administered into the caudal vein every other day for 16 days. Control mice receive an equal volume of vehicle (Salinomycinine) only. Body weight and tumor volume are monitored every two days. At the end of the experiments, tumors are excised, photographed, and weighed. Tumors from each group are used for western blotting and immunohistochemical (IHC) assay.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lu D, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7. [Content Brief]

[2]. Zhou J, et al. Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactiveoxygen species. Toxicol Lett. 2013 Oct 24;222(2):139-45. [Content Brief]

[3]. Klose J, et al. Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. PLoS One. 2019 Feb 14;14(2):e0211916. [Content Brief]

[4]. Wang F, et al. Salinomycin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells In Vitro and In Vivo. PLoS One. 2012; 7(12): e50638. [Content Brief]

[5]. Qu H, et al. Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24. Asian Pac J Trop Med. 2015 Jul;8(7):578-82. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2937 mL	6.4685 mL	12.9369 mL	32.3424 mL
	5 mM	0.2587 mL	1.2937 mL	2.5874 mL	6.4685 mL
	10 mM	0.1294 mL	0.6468 mL	1.2937 mL	3.2342 mL
	15 mM	0.0862 mL	0.4312 mL	0.8625 mL	2.1562 mL
	20 mM	0.0647 mL	0.3234 mL	0.6468 mL	1.6171 mL
	25 mM	0.0517 mL	0.2587 mL	0.5175 mL	1.2937 mL
	30 mM	0.0431 mL	0.2156 mL	0.4312 mL	1.0781 mL
	40 mM	0.0323 mL	0.1617 mL	0.3234 mL	0.8086 mL
	50 mM	0.0259 mL	0.1294 mL	0.2587 mL	0.6468 mL
	60 mM	0.0216 mL	0.1078 mL	0.2156 mL	0.5390 mL
	80 mM	0.0162 mL	0.0809 mL	0.1617 mL	0.4043 mL
	100 mM	0.0129 mL	0.0647 mL	0.1294 mL	0.3234 mL

Bioz

Keywords

Salinomycin sodium salt

52 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Salinomycin sodium salt

Publications Citing Use of MedChemExpress (MCE) Salinomycin sodium salt

All Wnt Isoforms

All Antibiotic Isoforms

All Parasite Isoforms